Market Update (NASDAQ:GILD): UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs

[Reuters] – Health insurer Anthem Inc on Thursday said it reached a deal under which Gilead Sciences Inc’s hepatitis C drug Harvoni will be the primary treatment for patients infected with the most . . . → Read More: Market Update (NASDAQ:GILD): UPDATE 1-Anthem selects Gilead as primary supplier of hepatitis C drugs Similar Articles: Company Update: Gilead Sciences Inc (NASDAQ:GILD) – U.S. FDA approves Gilead’s $94,500 hepatitis C drug Market Update: Gilead Sciences Inc (NASDAQ:GILD) – Gilead signs hepatitis C pact to cut drug cost for poor Stock Update (NASDAQ:GILD): UK cost body backs pricey Gilead hepatitis pill for some patients